HRD refers to the impairment or deficiency in the ability of cancer cells to repair DNA damage through the homologous recombination pathway. This pathway is crucial for the repair of double-stranded DNA breaks. By identifying HRD status in ovarian cancer By identifying HRD status in ovarian cancer, clinicians can better personalize treatment options and determine the most appropriate therapeutic interventions for patients, potentially improving treatment outcomes.
More Treatment Opportunities for Ovarian Cancer Patients
GC Genome’s HRD test provides targeted cancer therapy opportunities to 50% ovarian cancer patients. The existing genetic tests offered targeted cancer therapy opportunities to 20-30% of ovarian cancer patients. However, our HRD test selectively identifies HRD-positive patients, accounting for more than 50% of ovarian cancer patients, thereby providing targeted cancer therapy opportunities to a greater number of ovarian cancer patients.
Our New Approach to Ovarian Cancer, mRNA
GC Genome’s new tHRD(transcriptional HRD) test can more accurately detect patients who are responsive to drugs compared to the existing DNA-based HRD testing method. Our approach focused on a novel but widespread transcriptional mechanism by which HRD arises independently of BRCA1/2 mutations. This test can serve as a companion diagnostic for PARP inhibitors, providing valuable guidance in treatment decisions.
Our Publication on Cancer Research
Aberrant Transcript Usage Is Associated with
Homologous Recombination Deficiency and
Predicts Therapeutic Response